Breaking News Instant updates and real-time market news.

CRME

Cardiome

$2.76

-0.03 (-1.08%)

, AGN

Allergan

$189.99

-2.23 (-1.16%)

08:02
11/29/16
11/29
08:02
11/29/16
08:02

Cardiome advances towards launching XYDALBA in the UK

Cardiome (CRME) is pleased to announce that it has moved one step closer to launching XYDALBA in the UK by receiving an established price from the Secretary of State for Health, under regulation 3 of the Health Service Branded Medicines Regulations. Commenting on the development, Hugues Sachot, Senior Vice President Commercial at Cardiome said, "We are extremely pleased with the progress that XYDALBA continues to make toward our imminent launch in the UK and other European countries we have under license from Allergan (AGN). The creation of an established price does not guarantee reimbursement in the UK, but it is a critical step in preparation for launch by allowing Cardiome to start negotiating with individual hospitals to gain formulary access for XYDALBA. Cardiome expects to make its first commercial sale in the UK before the end of 2016. We also continue to receive excellent feedback from our other countries as we prepare to offer physicians access to this unique dosage regimen that provides a new treatment approach giving patients, healthcare professionals and hospitals greater flexibility in managing serious skin infections."

CRME

Cardiome

$2.76

-0.03 (-1.08%)

AGN

Allergan

$189.99

-2.23 (-1.16%)

  • 29

    Nov

CRME Cardiome
$2.76

-0.03 (-1.08%)

03/11/16
ADAM
03/11/16
NO CHANGE
Target $10
ADAM
Buy
Cardiome price target lowered to $10 from $16 at Canaccord
Canaccord lowered its price target on Cardiome to $10 from $16 following Q4 results. The firm cited its weak results, lowered guidance for the peak potential for Brinavess in Europe, and significant hurdles that remain for the U.S approval for Brinavess. Canaccord maintained its Buy rating on Cardiome shares.
06/01/16
HCWC
06/01/16
INITIATION
Target $9.5
HCWC
Buy
Cardiome initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth started Cardiome Pharma with a Buy rating and $9.50 price target.
08/02/16
ADAM
08/02/16
NO CHANGE
Target $9
ADAM
Speculative Buy
Cardiome price target lowered to $9 from $13.75 at Canaccord
Canaccord lowered its price target on Cardiome to $9 from $13.75 following its secondary offering of shares at a "big discount" to the previous closing of the stock. The firm believes the discount has presented a buying opportunity, as the recent licensing deal for Xydalba accelerates the company's transformation into a European hospital-focused specialty pharmaceuticals company. Canaccord reiterated its Speculative Buy rating on Cardiome shares.
AGN Allergan
$189.99

-2.23 (-1.16%)

11/04/16
UBSW
11/04/16
NO CHANGE
Target $240
UBSW
Buy
Allergan price target lowered to $240 from $300 at UBS
UBS analyst Marc Goodman lowered his price target on Allergan to $240 from $300 following disappointing Q3 results and a lowering of his estimates. However, Goodman reiterated his Buy rating on Allergan shares, on the belief it is still a good growth story, has an efficient tax structure and robust pipeline, and has the potential to put up double digit earnings growth for the rest of the decade.
11/21/16
WBLR
11/21/16
INITIATION
Target $209
WBLR
Market Perform
Allergan initiated with a Market Perform at William Blair
William Blair analyst Tim Lugo started Allergan with a Market Perform rating and $209 price target. The analyst views the company as high quality but sees headwinds in 2017 and 2018. Renewed competition for Botox could weigh on out-year estimates while a Namenda generic could come sooner than expected, Lugo tells investors in a research note.
11/21/16
11/21/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Netflix (NFLX) initiated with a Buy at Brean Capital. 2. Allergan (AGN) initiated with a Market Perform at William Blair. 3. Myovant Sciences (MYOV) was initiated with an Overweight at Barclays, an Outperform at JMP Securities, an Outperform at Baird, a Buy at Citi, and an Outperform at Cowen. 4. RA Pharmaceuticals (RARX) was initiated with a Buy at Jefferies, a Buy at SunTrust, and an Outperform at Credit Suisse. 5. ZTO Express (ZTO) was initiated with a Buy ratings at Citi and Goldman and an Overweight at Morgan Stanley. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/23/16
JMPS
11/23/16
NO CHANGE
JMPS
Adamas could have positive read through from Allergan deal, says JMP Securities
After Adamas' partner, Allergan (AGN), agreed to buy Chase Pharmaceuticals, JMP Securities analyst Jason Butler thinks that the deal could have positive implications for Adamas Pharmaceuticals and its Alzheimer's treatment, Namzaric, a combination therapy which blocks a neutrotransmitter. The analyst says that the deal "reinforces Allergan's long-term commitment to neurotransmitter focused" Alzheimer;s treatments and provides the opportunity for Chase's drug to be combined with Namzaric. The analyst thinks that such a combined drug could gain additional market share. He keeps a $29 price target and an Outperform rating on Adamas.

TODAY'S FREE FLY STORIES

VRX

Valeant

$17.15

0.5 (3.00%)

06:40
06/29/17
06/29
06:40
06/29/17
06:40
Technical Analysis
Technical View: Valeant moves higher in early trading »

The stock was last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Aug

BRK.A

Berkshire Hathaway

$254,660.00

3350 (1.33%)

, BRK.B

Berkshire Hathaway

$169.89

2.54 (1.52%)

06:38
06/29/17
06/29
06:38
06/29/17
06:38
Hot Stocks
Home Capital gets TSX approval for equity investment by Berkshire Hathaway »

Home Capital Group is…

BRK.A

Berkshire Hathaway

$254,660.00

3350 (1.33%)

BRK.B

Berkshire Hathaway

$169.89

2.54 (1.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNRO

Monro Muffler

$41.70

-3.45 (-7.64%)

06:36
06/29/17
06/29
06:36
06/29/17
06:36
Downgrade
Monro Muffler rating change  »

Monro Muffler downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHFS

CHF Solutions

$0.62

-0.0074 (-1.17%)

06:33
06/29/17
06/29
06:33
06/29/17
06:33
Initiation
CHF Solutions initiated  »

CHF Solutions initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MKC

McCormick

$98.95

0.42 (0.43%)

06:33
06/29/17
06/29
06:33
06/29/17
06:33
Earnings
McCormick backs FY17 adj. EPS view of $4.05-$4.13 »

Sees FY17 revenue up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

MKC

McCormick

$98.95

0.42 (0.43%)

06:31
06/29/17
06/29
06:31
06/29/17
06:31
Earnings
McCormick reports Q2 adj. EPS 82c, consensus 76c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

PIR

Pier 1 Imports

$5.38

0.04 (0.75%)

06:25
06/29/17
06/29
06:25
06/29/17
06:25
Recommendations
Pier 1 Imports analyst commentary  »

Pier 1 Imports shares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WB

Weibo

$69.36

0.28 (0.41%)

06:22
06/29/17
06/29
06:22
06/29/17
06:22
Recommendations
Weibo analyst commentary  »

Weibo content block to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WB

Weibo

$69.36

0.28 (0.41%)

, SINA

SINA

$86.75

1.78 (2.09%)

06:18
06/29/17
06/29
06:18
06/29/17
06:18
Periodicals
China's Weibo to block unlicensed video conternt, Reuters reports »

China's Weibo (WB)…

WB

Weibo

$69.36

0.28 (0.41%)

SINA

SINA

$86.75

1.78 (2.09%)

FENG

Phoenix New Media

$2.70

-0.04 (-1.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNP

CenterPoint Energy

$27.83

-0.35 (-1.24%)

06:13
06/29/17
06/29
06:13
06/29/17
06:13
Downgrade
CenterPoint Energy rating change  »

CenterPoint Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALSN

Allison Transmission

$37.89

0.65 (1.75%)

06:10
06/29/17
06/29
06:10
06/29/17
06:10
Recommendations
Allison Transmission analyst commentary  »

Piper 'growing more…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOAH

Noah Holdings

$27.69

1.13 (4.25%)

06:05
06/29/17
06/29
06:05
06/29/17
06:05
Hot Stocks
Noah Holdings authorizes $50M share repurchase program »

Noah Holdings has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GBX

Greenbrier

$50.00

0.55 (1.11%)

06:04
06/29/17
06/29
06:04
06/29/17
06:04
Earnings
Greenbrier sees FY17 EPS $3.45-$3.65, consensus $3.49 »

Sees FY17 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

  • 07

    Jul

PDS

Precision Drilling

$3.36

0.03 (0.90%)

06:04
06/29/17
06/29
06:04
06/29/17
06:04
Downgrade
Precision Drilling rating change  »

Precision Drilling…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GBX

Greenbrier

$50.00

0.55 (1.11%)

06:03
06/29/17
06/29
06:03
06/29/17
06:03
Earnings
Greenbrier reports Q3 EPS $1.03, consensus 82c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

  • 07

    Jul

SPX

S&P 500

06:01
06/29/17
06/29
06:01
06/29/17
06:01
Technical Analysis
S&P 500: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IMGN

ImmunoGen

$7.00

0.46 (7.03%)

06:01
06/29/17
06/29
06:01
06/29/17
06:01
Recommendations
ImmunoGen analyst commentary  »

ImmunoGen price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GDX

Market Vector Gold Miners

$22.43

0.17 (0.76%)

05:58
06/29/17
06/29
05:58
06/29/17
05:58
Technical Analysis
Market Vector Gold Miners: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLD

SPDR Gold Trust

$118.90

0.09 (0.08%)

05:57
06/29/17
06/29
05:57
06/29/17
05:57
Technical Analysis
SPDR Gold Trust: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NUGT

Direxion Gold Miners Bull

$31.99

0.49 (1.56%)

05:57
06/29/17
06/29
05:57
06/29/17
05:57
Technical Analysis
Direxion Gold Miners Bull: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNUG

Direxion Daily Jr Gld Mnrs Bull 3X Shrs

$19.69

0.8 (4.24%)

05:57
06/29/17
06/29
05:57
06/29/17
05:57
Technical Analysis
Direxion Daily Jr Gld Mnrs Bull 3X Shrs: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DUST

Direxion Daily Gold Miners Bear 3X ETF

$29.70

-0.63 (-2.08%)

05:56
06/29/17
06/29
05:56
06/29/17
05:56
Technical Analysis
Direxion Daily Gold Miners Bear 3X ETF: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JDST

Direxion Daily Junior Gold Miners Index Bear 3x Shares

$60.67

-2.77 (-4.37%)

05:56
06/29/17
06/29
05:56
06/29/17
05:56
Technical Analysis
Direxion Daily Junior Gold Miners Index Bear 3x Shares: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VXX

iPath S&P 500 VIX Short-Term Futures

$12.33

-0.34 (-2.68%)

05:49
06/29/17
06/29
05:49
06/29/17
05:49
Technical Analysis
iPath S&P 500 VIX Short-Term Futures: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XIV

VelocityShares Daily Inverse VIX Short-Term ETN

$86.47

2.38 (2.83%)

05:49
06/29/17
06/29
05:49
06/29/17
05:49
Technical Analysis
VelocityShares Daily Inverse VIX Short-Term ETN: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.